Fast Five Quiz: Type 2 Diabetes Incretin-Based Therapy

Romesh Khardori, MD, PhD; Anne L. Peters, MD


April 28, 2023

Because of their favorable efficacy and safety profile, DPP-4 inhibitors may be a therapeutic option for many patients with type 2 diabetes, especially older adults, patients with renal or hepatic impairments, and patients at risk for hypoglycemia. DPP-4 inhibitors carry a low incidence of adverse events such as hypoglycemia and gastrointestinal side effects and are considered weight neutral. In addition, studies have suggested that DPP-4 inhibitors may reduce albuminuria and improve various renal inflammatory markers.

Although DPP-4 inhibitors may be safe to use in patients with heart failure, they have not been shown to reduce adverse cardiovascular outcomes.

Learn more about DPP-4 inhibitors use in type 2 diabetes.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.